Pancreatic Cancer Research

Clinical trialPhase 1Recruiting

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

Outcome
Ongoing
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Start
2 June 2022
Expected end
31 August 2030
Enrollment
86 participants
Sites
3
Primary outcomes
Incidence of Dose-Limiting Toxicities (DLTs); Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Sponsor type
Industry
Results posted
No
Last update
25 September 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy

Detailed description public domain (ClinicalTrials.gov)

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IMC-002. Multiple-dose levels of IMC-002 will be tested in subjects with advanced cancer.